Foundation for Angelman Syndrome Therapeutics

02/19/2026

For two decades, the Angelman Syndrome Natural History Study has been building data that drives discovery.

Thanks to the dedication of clinicians, researchers, coordinator, individuals with Angelman syndrome, and their families, the AS Natural History Study has become a beacon of progress.

ASF and FAST are proud to celebrate this milestone with the Natural History Study team and the community that made it happen.

If you are interested in participating in the AS Natural History Study, click here to learn more: https://buff.ly/G61us1u

02/15/2026

Celebrate International Angelman Day with FAST!

Around the world, families, researchers, advocates, and partners are raising awareness of Angelman syndrome and pushing research forward. This day reflects the strength of a global community united by progress, persistence, and shared purpose.

Thank you to our global partners and affiliates for showing up and helping make Angelman syndrome visible today and every day.

If you’re able, consider making a donation to support the research moving this field forward. Every gift helps sustain momentum behind the science and the community driving it.

Donate here: https://buff.ly/jp19Xqc

02/14/2026

When Elizabeth O’Connor talks about Angelman syndrome, you feel both the love and the urgency. 💙

As Ryan’s mom, she’s living it. As FAST’s Philanthropy Manager, she’s helping push the work forward.

In her Fox 32 Chicago interview for International Angelman Day, Elizabeth shares what families carry every day with Angelman syndrome, and why they keep fighting: there is real momentum in the science. FAST is building that momentum by funding and accelerating the most promising research toward potential treatments.

Watch Elizabeth's interview and if she inspires you, please consider making a donation to help FAST fuel the research families are counting on. www.cureangelman.org/give

02/14/2026

In rare disease, “promising” isn’t enough.

The gap between an idea and a therapy is long, expensive, and full of unglamorous steps that still have to happen: the studies, the manufacturing work, the regulatory prep, the trial readiness. If that funding disappears, momentum slows, and families are left waiting.

That’s why patient organizations and families step in. Not because it’s easy, but because time matters.

If you want to help move Angelman syndrome research forward, a donation is a direct way to keep progress moving: https://buff.ly/jp19Xqc

02/13/2026

With International Angelman Day coming up, this is exactly the kind of story we want more people to see. It’s what makes the Angelman syndrome community extraordinary: families that turn love into action and build real momentum for research.

https://justiceforkids.com/hope-has-a-name-lisa-hoffman-angelman-syndrome-and-the-fight-for-a-brighter-future/

We’re so grateful to Lisa Hoffman, Heath's Heroes and everyone who shows up year after year to support Angelman syndrome research. 💙

Thank you to Justice for Kids for spotlighting this story!

Hope has a name—and for one incredible family, it’s Heath. 💛

In honor of International Angelman Day (Feb. 15), we’re sharing the story of one of our own: Lisa M. Hoffman, Justice for Kids Partner, devoted mother, and passionate advocate for children with disabilities both in and out of the office. Her son Heath was diagnosed with Angelman Syndrome at age two. And since then, Lisa has turned grief into purpose—and purpose into action.

Learn more about Lisa, Heath and Angelman Syndrome on the blog: https://justiceforkids.com/hope-has-a-name-lisa-hoffman-angelman-syndrome-and-the-fight-for-a-brighter-future/

02/13/2026

Awareness matters when it leads to listening.

For the Angelman syndrome community, progress depends on more than scientific discovery alone. It depends on understanding daily realities, priorities, and outcomes that matter most to people living with Angelman syndrome and the families who support them.

When lived experience is visible, it helps shape better research questions, more thoughtful clinical trials, and decisions that reflect real life. Awareness creates the space for those voices to be heard and taken seriously.

International Angelman Day is about visibility, but it’s also about what visibility makes possible. When people know Angelman syndrome exists, progress has a place to grow.

Learn why awareness matters beyond one day: angelmanadvocates.org

02/12/2026

Angelman syndrome affects families around the world, and progress depends on showing up together.

FAST works alongside global affiliates across Australia, Canada, Latin America, the UK, Poland, Germany, France, Spain, and Italy, all united by the same goal: advancing research and accelerating progress for people living with Angelman syndrome.

International Angelman Day is a reminder that this community stretches far beyond borders. Different languages, different healthcare systems, different lived experiences, all connected by shared urgency and shared hope.

We’re proud to stand with families, researchers, and advocates around the world.

Learn how Angelman syndrome research is advancing worldwide: https://cureangelman.org/global

02/11/2026

Through 2024, FAST has invested $64+ million to advance Angelman syndrome research and therapeutic development, including $53+ million in research grants (2011–2024) and $10+ million in mission-aligned venture investments (2022–2024).

That funding helps move programs from early discovery into real development, and closer to the clinic.

See what that investment is moving forward right now in the drug development pipeline:
🔗 https://cureangelman.org/current-pipeline

02/10/2026

Therapies don’t stall because the science isn’t interesting. They stall because the next step is expensive.

Estimates put the cost for a single program at roughly $67–$275 million. That range reflects what it takes to move a potential therapy through the long middle: preclinical studies, manufacturing, regulatory work, and clinical trials.

Rare disease communities can’t wait for progress to happen “someday.” Sustained funding is what keeps programs moving from idea to real progress.

You can help support the steps that make progress possible:
💸 https://buff.ly/jp19Xqc

02/09/2026

Drug development is long, even when the science is strong.

Across medicine, only a small fraction of potential therapies that start in early research ever make it all the way to patients. That’s why progress depends on investigating multiple promising approaches, learning quickly, and doubling down on what shows real potential.

This is the mindset behind FAST’s work: advance as many promising “shots on goal” as possible for the Angelman syndrome community.

If you want a clear, plain-language breakdown of how the drug development works, start here: https://buff.ly/8HujYUE

02/08/2026

Caregiving costs are not always visible, and they are not always medical.

A recent study puts numbers to the financial impact of Angelman syndrome—for U.S. families at nearly $80,000 per household—including the ripple effects on work and everyday life.

It looks beyond doctor visits to therapies and support services, equipment, transportation, and lost income.

Read more about the full analysis of the economic impact on families:
🔗 https://buff.ly/C7ePGdx

02/07/2026

Not being able to say “I’m hurt” or “I need help” changes everything.

For many people with Angelman syndrome, communication is complex and often nonverbal, which can make basic needs harder to express and harder to respond to quickly.

For the families caring for them, needs can become urgent quickly, and daily routines take more planning, more patience, and more support. This is one of the reasons families feel the impact of Angelman syndrome so intensely.

This is why research matters so much. Progress in Angelman syndrome isn’t only measured in milestones in a lab. It’s measured in everyday life: clearer ways to express needs, more connection, more autonomy, and fewer barriers to being understood.

If you want to help move that future closer, a donation is a concrete way to support the research driving it forward.
💸 https://buff.ly/jp19Xqc